Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Accumulated Expenses (2016 - 2025)

Iovance Biotherapeutics has reported Accumulated Expenses over the past 12 years, most recently at $111.2 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $111.2 million for Q4 2025, up 35.66% from a year ago — trailing twelve months through Dec 2025 was $111.2 million (up 35.66% YoY), and the annual figure for FY2025 was $111.2 million, up 35.66%.
  • Accumulated Expenses for Q4 2025 was $111.2 million at Iovance Biotherapeutics, up from $87.3 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for IOVA hit a ceiling of $111.2 million in Q4 2025 and a floor of $18.4 million in Q2 2023.
  • Median Accumulated Expenses over the past 3 years was $75.7 million (2023), compared with a mean of $66.0 million.
  • Biggest five-year swings in Accumulated Expenses: rose 7.77% in 2024 and later surged 82.41% in 2025.
  • Iovance Biotherapeutics' Accumulated Expenses stood at $69.4 million in 2023, then grew by 18.05% to $81.9 million in 2024, then skyrocketed by 35.66% to $111.2 million in 2025.
  • The last three reported values for Accumulated Expenses were $111.2 million (Q4 2025), $87.3 million (Q3 2025), and $89.1 million (Q2 2025) per Business Quant data.